Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Hepatitis pegylated interferon

De Rosa EG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Veronese L, Raiteri R, CaUeri G, Di Perri G (2006) The early HCV RNA dynamics in patients with acute hepatitis C treated with pegylated interferon-alpha2b. Antivir Ther 11 165-171 Di Bisceglie A (1997) Hepatitis D virus. Marcel Dekker, NY... [Pg.232]

Erhardt A, Gerlich W, Starke C, Wend U, Donner A, Sagir A, Heintges T, Haussinger D (2006) Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 26 805-810... [Pg.232]

Kozlowski A, Charles SA, Harris JM (2001) Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15 419 29 Krown SE, AeppU D, Balfour HH Jr (1999) Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 20 245-254 LaFleur DW, NardeUi B, Tsareva T, Mather D, Feng P, Semenuk M, Taylor K, Buergin M, Chinchilla D, Roshke V, Chen G, Ruben SM, Pitha PM, Coleman TA, Moore PA (2001) Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem 276 39765-39771... [Pg.236]

Niro GA, Rosina F, Rizzetto M (2005b) Treatment of hepatitis D. J Viral Hepat 12 2-9 Niro GA, Ciancio A, Gaeta GB, SmedUe A, Marrone A, OUvero A, Stanzione M, David E, Bran-caccio G, Fontana R, Perri F, AndriuUi A, Rizzetto M (2006) Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 44 713-720... [Pg.238]

Persons with confirmed chronic hepatitis B should be evaluated for treatment, which may include interferon, pegylated interferon, lamivudine, adefovir dipivoxil, or entecavir. The drug of choice for chronic hepatitis B depends on the patient s past medical history, aminotransferase level, HBV DNA level, and most importantly, HBeAg status. [Pg.353]

Interferon alfa is an antiviral agent that is effective in suppressing hepatitis B viral replication. Interferon alfa-2b and pegylated interferon alfa-2a are the only interferon therapies approved for the treatment of chronic hepatitis B. [Pg.353]

Pegylated interferon is interferon that is attached to a polyethylene glycol molecule that increases the half-life of the drug, thus allowing once-weekly dosing versus thrice-weekly administration required for the unmodified formulation. Pegylated interferon is well tolerated and is superior in efficacy to unmodified interferon for the treatment of chronic hepatitis B.26... [Pg.354]

The subcutaneous dose of interferon alfa-2b (Intron A) in patients who are HBsAg-positive is either 5 million units daily (better tolerated) or 10 million units three times weekly. The dose for HBsAg-negative patients is 5 to 6 million units three times weekly. The approved dose for pegylated interferon alfa-2a (Pegasys) for chronic hepatitis B is 180 meg subcutaneously once weekly. Interferon doses may need to be adjusted in patients with renal impairment. [Pg.354]

Individuals with confirmed chronic hepatitis C should be evaluated for treatment with pegylated interferon with or without ribavirin. [Pg.356]

At present, pegylated interferon plus ribavirin is the regimen of choice for the treatment of hepatitis C.41 Interferon, pegylated interferon, and ribavirin have significant adverse effects, as discussed below. [Pg.356]

Neutropenia associated with interferon or pegylated interferon therapy is defined as an absolute neutrophil count (ANC) of less than 1000 cells/mm3 in rare cases, an ANC less than 500 cells/mm3 maybe observed. The neutropenia is more common and in some cases more severe with pegylated interferon than with unmodified interferon. Neutropenia usually occurs within the first 2 weeks after initiating either formulation of interferon, with the WBC count stabilizing by week four or six. The neutropenia is reversible upon discontinuing therapy. Granulocyte colony-stimulating factor has been used as an adjunctive therapy for interferon-induced neutropenia in hepatitis patients.44... [Pg.356]

Aghemo A, Rumi MG, Colombo M (2010) Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 7 485 194... [Pg.137]

Jen, J.F. et al., Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C, Clin. Pharmacol. Then, 69, 407, 2001. [Pg.165]

Interferon is the approved treatment for hepatitis C. In general, there are four different treatments (1) IFN-a, (2) combination therapy of IFN-a and another drug called ribavirin, (3) pegylated IFN-a, and (4) pegylated IFN-a with ribavirin. Pegylated interferon contains polyethylene glycol, which increases the half-Ufe (see Section 5.3.5) from 6 hours to 45 hours and slows down the body s absorption of interferon. In this way, a more controlled release of interferon is achieved to prolong absorption. Instead of a subcutaneous injection of three times weekly, the frequency can be reduced to once weekly. [Pg.115]

Another perceived view about Western drugs is the adverse effects. Western medicine is sometimes viewed as a sledgehammer method rather than the more holistic approach using TM. The costs of Western medicine can be prohibitive as well, especially for patients in countries where there are no comprehensive healthcare systems. For example, treatment with pegylated interferon for hepatitis C or antibody for colon cancer can cost tens of thousands of dollars per year. Limitations of Western drugs in some cases, such as resistance to antibiotics, also highlight problems and pave the way for people to consider TM. See Exhibit 11.3 on how GlaxoSmithKline and... [Pg.364]

Lindsay, K.L., C. Trepo,T. Hemtges, et al., A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology, 2001. 34 395-403. [Pg.185]

Kozlowski, A., and J.M. Harris, Improvements in protein pegyylation pegylated interferons for treatment of hepatitis C. J Controlled Release, 2001. 72 217-224. [Pg.185]

Pegylated interferon alfa- 2a1 Chronic hepatitis 180 meg once weekly Subcutaneous... [Pg.1083]

Pegylated interferon alfa-l Chronic hepatitis 1.5 meg/kg once weekly with ribavirin (800 mg/d) or 1.0 meg/kg once weekly as Subcutaneous... [Pg.1083]

McHutchison JG, Fried MW Current therapy for hepatitis C Pegylated interferon and ribavirin. Clin Liver Dis 2003 7 149. [PMID 12691464]... [Pg.1209]

Pegylated interferon alfa-2b Chronic hepatitis C2 40-150 Mg once weekly, according to weight Subcutaneous... [Pg.1147]

See other pages where Hepatitis pegylated interferon is mentioned: [Pg.27]    [Pg.47]    [Pg.108]    [Pg.231]    [Pg.231]    [Pg.232]    [Pg.235]    [Pg.235]    [Pg.235]    [Pg.236]    [Pg.237]    [Pg.240]    [Pg.242]    [Pg.242]    [Pg.341]    [Pg.341]    [Pg.346]    [Pg.356]    [Pg.356]    [Pg.1267]    [Pg.291]    [Pg.173]    [Pg.60]    [Pg.421]    [Pg.1148]    [Pg.1149]   
See also in sourсe #XX -- [ Pg.353 ]

See also in sourсe #XX -- [ Pg.2 , Pg.88 , Pg.89 ]



SEARCH



Hepatitis, interferons

Interferons PEGylated

PEGylated

PEGylation

© 2024 chempedia.info